US WorldMeds Introduces Revonto For Malignant Hyperthermia

US WorldMeds said the time to reconstitute dantrolene sodium for injection has been reduced to approximately 20 seconds or until the solution is clear and Revonto retains the cost-savings of the original dantrolene sodium for injection product while offering an improvement in pharmacotherapy.

Revonto is a sterile, non-pyrogenic, lyophilized formulation of dantrolene sodium for injection. Revonto is supplied in 65ml vials containing 20mg dantrolene sodium, 3000mg mannitol, and sufficient sodium hydroxide to yield a pH of approximately 9.5 when reconstituted with 60ml sterile water for injection USP (without a bacteriostatic agent).

George Digenis, chief scientific officer of US WorldMeds, said: “The enhanced reconstitution time is an important and critical scientific improvement to intravenous dantrolene sodium, the only available antidote for the treatment of malignant hyperthermia.

“MH is triggered in some patients by certain inhalation anesthetics during surgery. A rapid response to MH onset is critical because temperatures exceeding 105F degrees and death due to this condition can occur as early as 30 minutes from onset.”